Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans (Q28199325)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: September 2003)

Language	Label	Description	Also known as
English	Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans	scientific article (publication date: September 2003)

Statements

scholarly article

0 references

Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans (English)

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jochen Graff

1

0 references

Ute Klinkhardt

2

0 references

Dagmar Westrup

3

0 references

Carl M Kirchmaier

4

0 references

Hans Klaus Breddin

5

0 references

Sebastian Harder

6

0 references

language of work or name

0 references

publication date

September 2003

0 references

British Journal of Clinical Pharmacology

0 references

56

0 references

3

0 references

321-6

0 references

Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

20 March 2017

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

29 September 2017

Interaction between the LMWH reviparin and aspirin in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

29 September 2017

Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

29 September 2017

Primary haemostasis: sticky fingers cement the relationship

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

29 September 2017

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

29 September 2017

Mechanisms of thromboembolism at arterial plaques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

29 September 2017

Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

2 June 2018

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

2 June 2018

Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

2 June 2018

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

20 June 2018

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2003.01873.X

21 January 2018

Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2003.01873.X

21 January 2018

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

27 November 2018

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

27 November 2018

Defective platelet activation in G alpha(q)-deficient mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884347

27 November 2018

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2003.01873.X

21 January 2018

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2003.01873.X

21 January 2018

Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2003.01873.X

21 January 2018

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2003.01873.X

21 January 2018

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of platelet function assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The collagen-platelet interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation between inhibition of platelet aggregation and clinical outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GMP-140 mediates adhesion of stimulated platelets to neutrophils

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heparin potentiation of collagen-induced platelet aggregation is related to the GPIIb/GPIIIa receptor and not to the GPIb receptor, as tested by whole blood aggregometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A

1 reference

https://pubmed.ncbi.nlm.nih.gov/12919181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1046/J.0306-5251.2003.01873.X

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28199325&oldid=1585767526"